Article

FDA-approved laser system treats high myopia with astigmatism

The FDA has granted approval for Advanced Medical Optics’ (AMO) STAR S4 IR excimer laser system for the treatment of high myopia and myopic astigmatism.

With the CustomVue wavefront-guided LASIK procedure, indications include the reduction or elimination of myopia and myopic astigmatism from –6 to –11 D with up to –3 D of cylinder. Clinical studies found that at 6 months, in 98.3% of those who received the CustomVue high-myopia treatment vision was corrected to 20/40 or better and in 84.3% it was corrected to 20/20 or better without spectacles or corrective contact lenses, according to AMO.

CustomVue procedures for high myopia will be released to doctors certified in VISX technology over the next several weeks after they have completed the training and certification process.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.